PD DR. Martin Reist becomes new CEO of SAKK

The SAKK Board has elected PD Dr. Martin Reist as the new CEO of the Swiss Group for Clinical Cancer Research (SAKK). He will take office in mid-August 2019, succeeding Dr. Peter Brauchli, who left SAKK at the end of November 2018.

PD DR. Martin Reist becomes new CEO of SAKK

The SAKK Board has elected PD Dr. Martin Reist as the new CEO of the Swiss Group for Clinical Cancer Research (SAKK). He will take office in mid-August 2019, succeeding Dr. Peter Brauchli, who left SAKK at the end of November 2018.

Martin Reist

The 47-year-old Martin Reist convinced the SAKK Board with his extensive experience as researcher, scientist and manager of complex expert organisations as well as with his expertise at the interface of science, industry and the public sector. Martin Reist currently runs his own consulting firm. Previously, he successfully managed and developed several strategically important areas at the federal government of health. He holds a double doctorate (Dr. med. vet. University of Zurich and Dr. sc. nat. ETH) and a faculty position at the Veterinary Public Health Institute of the University of Bern.

Martin Reist is married and lives with his family in Bern.
The SAKK Board is highly convinced that PD Dr. Martin Reist is an excellent candidate for the CEO position and wishes him every success in his new position.                       

All News